<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The erythropoietic effects of lenalidomide are cytokine dependent, suggesting that the erythroid hematologic improvement (HI-E) rate may be augmented by combined treatment (CT) with recombinant human erythropoietin (rhu-EPO) in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we explored the benefits of CT and the relationship between lenalidomide pharmacokinetics and hematologic toxicity in transfusion-dependent patients with low- to intermediate-1-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who failed prior rhu-EPO </plain></SENT>
<SENT sid="2" pm="."><plain>In stage I, patients received 10 or 15 mg/d of lenalidomide monotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>At week 16, erythroid nonresponders (NRs) were eligible for CT with rhu-EPO 40 000 U/wk </plain></SENT>
<SENT sid="4" pm="."><plain>Among 39 patients, HI-E response rate to monotherapy was 86% (6 of 7) in del(5q) and 25% (8 of 32) in non-del(5q) patients (10 mg, 17.7%; 15 mg, 33.3%) </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-three patients proceeded to CT, with 6 (26.0%) achieving HI-E </plain></SENT>
<SENT sid="6" pm="."><plain>In 19 non-del(5q) patients, 4 (21.1%) showed HI-E </plain></SENT>
<SENT sid="7" pm="."><plain>Mean baseline serum EPO in non-del(5q) patients was lower in monotherapy and CT responders than in NR (not statistically significant) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> was significantly correlated with lenalidomide area under the plasma concentration-time curve (P = .0015), but severity of <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> did not </plain></SENT>
<SENT sid="9" pm="."><plain>The benefits of lenalidomide plus rhu-EPO are currently under investigation in a phase 3 Eastern Cooperative <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group (ECOG)-sponsored intergroup study </plain></SENT>
<SENT sid="10" pm="."><plain>This study is registered at www.clinicaltrials.gov as NCT00910858 </plain></SENT>
</text></document>